Treatment of opioid dependency with depot buprenorphine products – Buvidal® and Sublocade® Part 1

Part 2 available here    • Treatment of opioid dependency with d...  
This webinar aims to explain the clinical guidance, evidence base, pharmacology, and risks associated with depot buprenorphine, and how to implement it as an Opioid Agonist Treatment for opioid dependency. We will discuss skills to help you identify suitable patients for depot buprenorphine and have conversations about the risks and benefits, and how to comply with the regulatory requirements of prescribing and storing of depot buprenorphine.
The webinar is presented by Assoc Professor Nicholas Lintzeris, Clinical Director of South Eastern Sydney Local Health District on 16 June 2020

By the end of this training clinicians will be able to:
• Explain the clinical guidance, evidence base, pharmacology, and risks associated with depot buprenorphine
• Identify patients suitable for depot buprenorphine, and have clinical conversations about the risks and benefits of depot buprenorphine with patients
• Implement depot buprenorphine as an opioid agonist treatment for opioid dependency, specifically in relation to prescribing, induction, dose alterations and reduction off the drug
• Administer subcutaneous injection of depot buprenorphine
• Comply with the regulatory requirements of prescribing and storing of depot buprenorphine

For more information on Depot Buprenorphine, including clinical guidelines see: https://www.health.nsw.gov.au/aod/Pag...